Abstract Details

Title Translating Real-world Practice Patterns into Improved Care for Agitation Associated with Dementia due to Alzheimer’s Disease: Results from a Multimodal, Multidisciplinary ��ɫ��al Initiative

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) P6 - Poster Session 6 (5:00 PM-6:00 PM)

Poster/Presentation
Number 12-002

Objective To evaluate the impact of a multimodal educational initiative on clinician knowledge and competence in recognizing and managing agitation associated with dementia due to Alzheimer’s disease (AADAD).

Background While FDA approved treatments for AADAD are now available; they are underutilized in care. Additionally, screening tools are often inconsistently applied, leading to diagnostic delays, caregiver overwhelm, and greater risk of institutionalization.

Design/Methods The initiative comprised three sequential components. The first was a national online practice-pattern survey of neurologists and psychiatrists to identify barriers in care. This informed a patient-centered roundtable discussion (panelists included an expert neurologist, psychiatrist, nurse practitioner, social worker, occupational and recreational therapists, and caregivers), which in turn formed the basis of a four-module CME curriculum, highlighting strategies to optimize early identification, treatment selection, and team-based care. ��ɫ��al impact was assessed through pre- and post-tests and intended practice changes. Chi-square tests compared responses (P < 0.05; pre/post).

Results Survey results (n = 120) found only 22% of clinicians felt prepared to counsel patients on new therapies and few routinely used validated screening tools. Roundtable participants emphasized the need for consistent terminology and structured caregiver engagement. Overall, 3,205 clinicians participated in the CME modules (51% psychiatry/geriatric medicine, 19% neurology, 8% primary care, 22% other). Mean post-test scores improved by 16%-31% (P < .05). Improvements related to awareness of AADAD symptoms and screening tools (21%-29%), understanding of AADAD pathophysiology (16%-23%), and correct application of novel therapies (31%). Sixty-five percent of neurologists and 75% of psychiatrists reported greater likelihood of multidisciplinary collaboration.

Conclusions This multimodal educational initiative improved clinician knowledge and competence in recognizing and managing AADAD, supporting more consistent, evidence-based management. Ongoing education is needed to sustain these gains and translate them into improved outcomes for patients and caregivers.

Authors/Disclosures
Vandana Gupta, MSc PRESENTER	Ms. Gupta has nothing to disclose.
Carole Drexel (PlatformQ LLC)	Carole Drexel has nothing to disclose.
Alireza Atri, MD, PhD (Banner Sun Health Research Institute)	Dr. Atri has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Prothena. Dr. Atri has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Eisai. Dr. Atri has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novo Nordisk. Dr. Atri has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Atri has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Atri has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Life Molecular Imaging. Dr. Atri has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novo Nordisk. Dr. Atri has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche/Genentech. Dr. Atri has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lunbeck. Dr. Atri has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ONO. Dr. Atri has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Axsome. Dr. Atri has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AriBio. Dr. Atri has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Vaxxinity. The institution of Dr. Atri has received research support from National Institute of Aging (NIA). The institution of Dr. Atri has received research support from AZ Department of Health Services. The institution of Dr. Atri has received research support from Gates Ventures. The institution of Dr. Atri has received research support from Multiple companies, universities & consortia for contracted clinical trials to institution. The institution of Dr. Atri has received research support from Washington University in St. Louis. The institution of Dr. Atri has received research support from Foundation for NIH. The institution of Dr. Atri has received research support from ACTC/NIH. Dr. Atri has received publishing royalties from a publication relating to health care.
George Grossberg, MD (St Louis University School of Medicine Department of Neurology & Psychiatry)	Dr. Grossberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Axsome Therapeutics. Dr. Grossberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Grossberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BioXcel. Dr. Grossberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Dr. Grossberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Grossberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Karuna. Dr. Grossberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Grossberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Maplight Therapeutics. Dr. Grossberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Otsuka. Dr. Grossberg has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Takeda. The institution of Dr. Grossberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Anavex. The institution of Dr. Grossberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. The institution of Dr. Grossberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Newron. The institution of Dr. Grossberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Oligomerix. The institution of Dr. Grossberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Quince. Dr. Grossberg has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Grossberg has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eisai. Dr. Grossberg has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Otsuka. The institution of Dr. Grossberg has received research support from NIA. The institution of Dr. Grossberg has received research support from Functional Neuromodulation .

��ɫ����

��ɫ����

��ɫ��

��ɫ��